133 related articles for article (PubMed ID: 29893327)
1. The clinical importance of serum urokinase plasminogen activator receptor and carbonic anhydrase IX levels and the effect of anthracycline-based adjuvant chemotherapy on these biomarkers in breast cancer.
Topcu TO; Ozdemir F; Kavgaci H; Gunaldi M; Kocoglu H; Imamoglu GI; Mentese A; Yaman SO; Orem A; Aydin F
J Cancer Res Ther; 2018; 14(3):608-613. PubMed ID: 29893327
[TBL] [Abstract][Full Text] [Related]
2. Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer.
Generali D; Fox SB; Berruti A; Brizzi MP; Campo L; Bonardi S; Wigfield SM; Bruzzi P; Bersiga A; Allevi G; Milani M; Aguggini S; Dogliotti L; Bottini A; Harris AL
Endocr Relat Cancer; 2006 Sep; 13(3):921-30. PubMed ID: 16954440
[TBL] [Abstract][Full Text] [Related]
3. The effect of anthracycline-based (epirubicin) adjuvant chemotherapy on plasma TAFI and PAI-1 levels in operable breast cancer.
Demirkan B; Ozcan MA; Glu AA; Yüksel F; Undar B; Alakavuklar M
Clin Appl Thromb Hemost; 2006 Jan; 12(1):9-14. PubMed ID: 16444429
[TBL] [Abstract][Full Text] [Related]
4. Circulating Carbonic Anhydrase IX and Antiangiogenic Therapy in Breast Cancer.
Brown-Glaberman U; Marron M; Chalasani P; Livingston R; Iannone M; Specht J; Stopeck AT
Dis Markers; 2016; 2016():9810383. PubMed ID: 26941473
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial.
Janning M; Müller V; Vettorazzi E; Cubas-Cordova M; Gensch V; Ben-Batalla I; Zu Eulenburg C; Schem C; Fasching PA; Schnappauf B; Karn T; Fehm T; Just M; Kühn T; Holms F; Overkamp F; Krabisch P; Rack B; Denkert C; Untch M; Tesch H; Rezai M; Kittel K; Pantel K; Bokemeyer C; Loibl S; von Minckwitz G; Loges S
Int J Cancer; 2019 Aug; 145(3):857-868. PubMed ID: 30694523
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast Cancer.
Schramm A; Schochter F; Friedl TWP; de Gregorio N; Andergassen U; Alunni-Fabbroni M; Trapp E; Jaeger B; Heinrich G; Camara O; Decker T; Ober A; Mahner S; Fehm TN; Pantel K; Fasching PA; Schneeweiss A; Janni W; Rack BK;
Clin Breast Cancer; 2017 Jul; 17(4):279-285. PubMed ID: 28190761
[TBL] [Abstract][Full Text] [Related]
7. Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer.
Müller V; Riethdorf S; Rack B; Janni W; Fasching PA; Solomayer E; Aktas B; Kasimir-Bauer S; Zeitz J; Pantel K; Fehm T;
Breast Cancer Res; 2011 Jul; 13(4):R71. PubMed ID: 21745383
[TBL] [Abstract][Full Text] [Related]
8. Impact of serum HER2, TIMP-1, and CAIX on outcome for HER2+ metastatic breast cancer patients: CCTG MA.31 (lapatinib vs. trastuzumab).
Ho D; Huang J; Chapman JW; Leitzel K; Ali SM; Shepherd L; Parulekar WR; Ellis CE; Crescnzo RJ; Zhu L; Virk S; Nomikos D; Aparicio S; Gelmon KA; Carney WP; Lipton A
Breast Cancer Res Treat; 2017 Aug; 164(3):571-580. PubMed ID: 28484925
[TBL] [Abstract][Full Text] [Related]
9. Serum carbonic anhydrase IX and its prognostic relevance in vulvar cancer.
Kock L; Mahner S; Choschzick M; Eulenburg C; Milde-Langosch K; Schwarz J; Jaenicke F; Müller V; Woelber L
Int J Gynecol Cancer; 2011 Jan; 21(1):141-8. PubMed ID: 21330838
[TBL] [Abstract][Full Text] [Related]
10. CAIX is a predictor of pathological complete response and is associated with higher survival in locally advanced breast cancer submitted to neoadjuvant chemotherapy.
Alves WEFM; Bonatelli M; Dufloth R; Kerr LM; Carrara GFA; da Costa RFA; Scapulatempo-Neto C; Tiezzi D; da Costa Vieira RA; Pinheiro C
BMC Cancer; 2019 Dec; 19(1):1173. PubMed ID: 31795962
[TBL] [Abstract][Full Text] [Related]
11. Relevance of cellular and serum carbonic anhydrase IX in primary breast cancer.
Schütze D; Milde-Langosch K; Witzel I; Rody A; Karn T; Schmidt M; Choschzick M; Jänicke F; Müller V
J Cancer Res Clin Oncol; 2013 May; 139(5):747-54. PubMed ID: 23358720
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic and prognostic significance of CA IX and suPAR in gastric cancer.
Fidan E; Mentese A; Ozdemir F; Deger O; Kavgaci H; Caner Karahan S; Aydin F
Med Oncol; 2013 Jun; 30(2):540. PubMed ID: 23512428
[TBL] [Abstract][Full Text] [Related]
13. A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer.
Ishiguro H; Masuda N; Sato N; Higaki K; Morimoto T; Yanagita Y; Mizutani M; Ohtani S; Kaneko K; Fujisawa T; Takahashi M; Kadoya T; Matsunami N; Yamamoto Y; Ohno S; Takano T; Morita S; Tanaka-Mizuno S; Toi M
Breast Cancer Res Treat; 2020 Apr; 180(3):715-724. PubMed ID: 32170634
[TBL] [Abstract][Full Text] [Related]
14. Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial.
Fumoleau P; Kerbrat P; Romestaing P; Fargeot P; Brémond A; Namer M; Schraub S; Goudier MJ; Mihura J; Monnier A; Clavère P; Serin D; Seffert P; Pourny C; Facchini T; Jacquin JP; Sztermer JF; Datchary J; Ramos R; Luporsi E
J Clin Oncol; 2003 Jan; 21(2):298-305. PubMed ID: 12525522
[TBL] [Abstract][Full Text] [Related]
15. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial.
French Adjuvant Study Group
J Clin Oncol; 2001 Feb; 19(3):602-11. PubMed ID: 11157009
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer-specific mRNA transcripts presence in peripheral blood after adjuvant chemotherapy predicts poor survival among high-risk breast cancer patients treated with high-dose chemotherapy with peripheral blood stem cell support.
Quintela-Fandino M; López JM; Hitt R; Gamarra S; Jimeno A; Ayala R; Hornedo J; Guzman C; Gilsanz F; Cortés-Funes H
J Clin Oncol; 2006 Aug; 24(22):3611-8. PubMed ID: 16877728
[TBL] [Abstract][Full Text] [Related]
17. The prognostic value of the soluble urokinase-type plasminogen activator receptor (s-uPAR) in plasma of breast cancer patients with and without metastatic disease.
Nijziel MR; Van Oerle R; Hellenbrand D; Van Pampus EC; Hillen HF; Hamulyák K
J Thromb Haemost; 2003 May; 1(5):982-6. PubMed ID: 12871365
[TBL] [Abstract][Full Text] [Related]
18. The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy.
Tan EY; Yan M; Campo L; Han C; Takano E; Turley H; Candiloro I; Pezzella F; Gatter KC; Millar EK; O'Toole SA; McNeil CM; Crea P; Segara D; Sutherland RL; Harris AL; Fox SB
Br J Cancer; 2009 Jan; 100(2):405-11. PubMed ID: 19165203
[TBL] [Abstract][Full Text] [Related]
19. Prognostic relevance of carbonic anhydrase IX expression is distinct in various subtypes of breast cancer and its silencing suppresses self-renewal capacity of breast cancer cells.
Ivanova L; Zandberga E; Siliņa K; Kalniņa Z; Ābols A; Endzeliņš E; Vendina I; Romanchikova N; Hegmane A; Trapencieris P; Eglītis J; Linē A
Cancer Chemother Pharmacol; 2015 Feb; 75(2):235-46. PubMed ID: 25422154
[TBL] [Abstract][Full Text] [Related]
20. Carbonic anhydrase 9 is associated with chemosensitivity and prognosis in breast cancer patients treated with taxane and anthracycline.
Aomatsu N; Yashiro M; Kashiwagi S; Kawajiri H; Takashima T; Ohsawa M; Wakasa K; Hirakawa K
BMC Cancer; 2014 Jun; 14():400. PubMed ID: 24893880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
